Loading...
Loading...
MRNS| Name | Value |
|---|---|
| Revenues | 8.1M |
| Cost of Revenue | 0.9M |
| Gross Profit | 7.2M |
| Operating Expense | 37.5M |
| Operating I/L | -30.3M |
| Other Income/Expense | -5.5M |
| Interest Income | 1.1M |
| Pretax | -35.8M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -35.8M |
Marinus Pharmaceuticals, Inc. is a pharmaceutical company specializing in the development and commercialization of products for rare genetic epilepsies and seizure disorders. Its flagship product, ZTALMY, is an oral suspension designed to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in both adult and pediatric patients. The company's product candidate, ganaxolone, is being developed for various genetic epilepsy disorders and depressive disorders. Marinus Pharmaceuticals, Inc. generates revenue through the sale of its ZTALMY product and potential future sales of ganaxolone, targeting the anti-seizure, antidepressant, and anxiolytic market segments.
